Posts in the “Immunotherapy Immunotherapy” category:

Johnson & Johnson Innovation Announces Immuno-Oncology Lung Cancer Collaboration with the Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science

Posted by Samantha Powell on June 23rd, 2014 |

Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. today announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber’s Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen’s lung cancer discovery […]

Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment – KOL Insight

Posted by Samantha Powell on June 10th, 2014 |

Change is coming to the NSCLC treatment algorithm—and it’s coming soon. Revolutionary new immunotherapies, more personalised treatment choices and further drug developments are all set to roll out in the near future. What are the potential blockbusters, who will gain approvals first and what are the future challenges? Drivers of change – Revolutionary immunotherapies. From […]

Phase III Immunotherapy Lung Cancer Trial Stopped Early

Posted by Samantha Powell on April 18th, 2014 |

Date: 4/18/14 Outlet Full Name: Cancer Network Author: Dave Levitan http://www.cancernetwork.com/lung-cancer/phase-iii-immunotherapy-lung-cancer-trial-stopped-early GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment. Vincent Brichard, the senior vice-president and head of immunotherapeutics at the company […]

Immunotherapy Data Marks New Era for Treating Lung Cancer

Posted by Samantha Powell on April 14th, 2014 |

Date: 4/14/14 Outlet Full Name: Oncology Nurse Advisor Author: Kathy Boltz http://www.oncologynurseadvisor.com/immunotherapy-data-marks-new-era-for-treating-lung-cancer/article/342366/ A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts said at the Fourth European Lung Cancer Congress (ELCC) in Geneva, Switzerland. For decades, scientists and doctors thought immunotherapy, […]

UT Southwestern Medical Center Scientists Present on Anti-Cancer Agent Bavituximab at AACR

Posted by Samantha Powell on April 9th, 2014 |

Date: 4/9/14 Outlet Full Name: Bio News Texas Author: Maureen Newman http://bionews-tx.com/news/2014/04/09/ut-southwestern-medical-center-scientists-present-on-anti-cancer-agent-bavituximab-at-aacr/ Data obtained at the University of Texas Southwestern Medical Center and funded by a grant from the Cancer Prevention Research Institute of Texas was presented at the American Association for Cancer Research this week in San Diego, California. The presenting author of the […]

Immunotherapy Data Heralds New Era of Lung Cancer Treatment

Posted by Samantha Powell on March 26th, 2014 |

Date: 3/26/14 Outlet Full Name: Medical News Today Author: No author http://www.medicalnewstoday.com/releases/274533.php A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy – treatments that […]

Glaxo’s Immunotherapy Fails to Help Lung Cancer Patients

Posted by Samantha Powell on March 20th, 2014 |

Date: 3/20/14 Outlet Full Name: Bloomberg News Author: Allison Connolly, Makiko Kitamura http://www.bloomberg.com/news/2014-03-20/glaxo-s-cancer-medicine-fails-to-meet-goal-of-trial.html An experimental GlaxoSmithKline Plc (GSK) product didn’t work in a lung cancer study, the second time the medicine failed an advanced test against cancer. The therapy known as MAGE-A3 didn’t help patients with non-small cell lung cancer live longer without the disease […]